AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34229149
Drug: amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin plus prednisolone
Trial: 34229149
Drug: metamizole/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metamizole/acetaminophen
Trial: 33350170
Drug: Cyclophosphamide (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (placebo treatment period)
Trial: 35502452
Drug: Coaching program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaching program (physical activity, home visits, weekly phone calls)
Trial: 34182603
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen up to 60 l.min-1 at 100% FIO2
Trial: 34182603
Drug: Low-flow nasal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow nasal oxygen at 4 l.min-1 plus oxygen through an oxygenating mouthguard totalling 8 l.min-1
Trial: 33858441
Drug: Low sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sulfur amino acid (SAA) diet (total diet SAA 15–25 mg/kg body weight/day)
Trial: 33858441
Drug: High sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sulfur amino acid (SAA) diet (total diet SAA 50–60 mg/kg body weight/day)
Trial: 33439140
Drug: Sanadak app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sanadak app (cognitive behavioral therapy-based self-help)
Trial: 35267246
Drug: Luseogliflozin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin (2.5 mg, once daily)
Trial: 35267246
Drug: Voglibose (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.2 mg, three times daily)
Trial: 36277941
Drug: Weekly voice
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly voice message intervention transmitted through mobile phone from recruitment in the first trimester until two weeks postpartum.
Trial: 34474578
Drug: Passive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive treatment and education
Trial: 32452142
Drug: Female hormones
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Female hormones users
Trial: 33006952
Drug: Electrical vestibular
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical vestibular nerve stimulation (VeNS) administered for 30 minutes, 1 hour prior to sleep onset for 14 days using ML1000 device (Neurovalens, UK)
Trial: 34448694
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (250 mg) in fasting group
Trial: 34448694
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (250 mg) in fasting group
Trial: 34448694
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (250 mg) in postprandial group
Trial: 34448694
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (250 mg) in postprandial group
Trial: 32746952
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g daily of 99% cocoa chocolate for 6 months
Trial: 35151410
Drug: Balovaptan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balovaptan (10 mg daily for 24 weeks)
Trial: 32697556
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol maleate administered by a trained clinician
Trial: 36314321
Drug: Omega-3 +
RxNorm normalized name: Walgreens Finest Nutrition OMEGA-3 + D Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 + standard therapy (hydroxyurea and folic acid daily with ibuprofen as needed)
Trial: 36314321
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D + standard therapy (hydroxyurea and folic acid daily with ibuprofen as needed)
Trial: 34632922
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (50 Gy in 25 fractions)
Trial: 34632922
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (40 Gy in 15 fractions)
Trial: 34632922
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy with anatomical evaluation
Trial: 32456617
Drug: DL-3-n-butylphthalide (NBP)
RxNorm normalized name: DL-3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-3-n-butylphthalide (NBP) 200 mg three times daily for four weeks
Trial: 32456617
Drug: Placebo 20
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20 mg three times daily for four weeks
Trial: 32811342
Drug: Radioiodine (RAI)
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine (RAI) treatment, fixed dose of 15 mCi
Trial: 32811342
Drug: Long-term Methimazole
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term Methimazole (MMI) treatment, starting dose of 10 mg daily, decreased to 4.9±1.0, 4.3±1.0, 4.4±1.4, 4.3±1.8, and 3.7±1.3 mg after 1, 2, 3, 4, and 5 years respectively
Trial: 32051177
Drug: AI2 personal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI2 personal nudging system (text messages for missed medications or health checks)
Trial: 33960149
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of empagliflozin for 12 weeks
Trial: 33387427
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy only in 20 patients (comparison group).
Trial: 32948554
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of intravenous crystalloid
Trial: 32948554
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous fluid bolus
Trial: 35276967
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran supplementation (1–5 g/day for 6 months)
Trial: 32180155
Drug: BoNT‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injection into the pectoralis major and teres major muscles
Trial: 33401219
Drug: Atorvastatin (ATORVA)
RxNorm normalized name: atorvastatin Oral Suspension [Atorvaliq]
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (ATORVA) 40 mg daily for 6 months
Trial: 33401219
Drug: Rosuvastatin (ROSUVA)
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (ROSUVA) 10 mg daily for 6 months
Trial: 32134758
Drug: Intracoronary Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary Adenosine (two bolus doses)
Trial: 32295779
Drug: Psychotherapy as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy as treatment as usual
Trial: 34569538
Drug: CMV‐HyperIg treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV‐HyperIg treatment upon seroconversion
Trial: 36217901
Drug: RP7214 single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP7214 single-dose (100, 200, and 400 mg QD)
Trial: 36217901
Drug: RP7214 food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP7214 food effect (single dose of 200 mg)
Trial: 35536579
Drug: Community and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community and clinic education intervention program (Ask About Aspirin campaign)
Trial: 36086876
Drug: Steroid-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-eluting stents containing mometasone furoate
Trial: 36086876
Drug: Control side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control side (no steroid-eluting stents)
Trial: 32622913
Drug: eGFR≤30 mL/min/1.73m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR≤30 mL/min/1.73m2 or renal replacement therapy
Trial: 34033120
Drug: Bifonazole solution
RxNorm normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole solution
Trial: 35590347
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity (once daily) CTAR‐SwiFt exercise
Trial: 35590347
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity (twice daily) CTAR‐SwiFt exercises
Trial: 34271953
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of Astragalus Membranaceus Root (AMR)
Trial: 32162497
Drug: Experimental transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental transdermal gel (ETG)
Trial: 32162497
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (PTG)
Trial: 32162497
Drug: Complete multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete multimodal treatment (ETG + external therapies, art therapies, neurofunctional reorganization)
Trial: 32162497
Drug: Weekly external
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly external therapies, art therapies, and neurofunctional reorganization with ETG
Trial: 615270428
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of unruptured AVMs grade 1 and 2
Trial: 615270428
Drug: Treatment strategy
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment strategy defined by multidisciplinary team
Trial: 32020565
Drug: Prolonged-release oxycodone/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release oxycodone/naloxone (OXN PR)
Trial: 32020565
Drug: Prolonged-release oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release oxycodone (OXY PR)
Trial: 33730384
Drug: CBT4CBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT4CBT plus treatment as usual (CBT4CBT+TAU)
Trial: 32842839
Drug: Culturally-adapted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally-adapted treatment (CAT)
Trial: 32842839
Drug: Standard evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard evidence-based treatment (EBT)
Trial: 35934663
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for OAB)
Trial: 32776430
Drug: One cup
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cup of espresso coffee plus two CBPCC twice per day
Trial: 32460699
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) 0.4 μg/kg over 10 mins followed by 0.4 μg/kg/h till the second day morning after surgery
Trial: 32460699
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) administered similarly to DEX group
Trial: 32945145
Drug: Psychological interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological interventions (CBT and CBT + add on treatment)
Trial: 32945145
Drug: More than
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More than 20 treatment sessions
Trial: 32579776
Drug: JNJ-56136379 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 (25 mg)
Trial: 32579776
Drug: JNJ-56136379 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 (75 mg)
Trial: 32579776
Drug: JNJ-56136379 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 (150 mg)
Trial: 34086631
Drug: 800-mg orally
RxNorm normalized name: piracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800-mg orally administered CBD
Trial: 32648983
Drug: Ketamine mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine mouthwash (4 mg/mL solution; dose 1 mg/kg)
Trial: 33374970
Drug: Low-iron formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-iron formula (2 mg/L) fortified with bovine lactoferrin (1.0 g/L)
Trial: 33374970
Drug: Low-iron formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-iron formula unfortified with lactoferrin (2 mg/L)
Trial: 33374970
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula with 8 mg of iron/L and no lactoferrin fortification (Control)
Trial: 35633589
Drug: Hyperchloremia (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperchloremia (defined as 110 mmol/L or greater) with two or more occurrences within 48 hours
Trial: 33899452
Drug: High-intensity laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity laser therapy
Trial: 33899452
Drug: Fractional radiofrequency
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional radiofrequency therapy
Trial: 33899452
Drug: Combined methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined methods (high-intensity laser therapy or micro-needling in combination with peels, fillers, PRP injection)
Trial: 33899452
Drug: Micro-needling as
RxNorm normalized name: Salicylic Acid 0.002 TOPICAL PATCH [Egg micro needle soothing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-needling as monotherapy
Trial: 33310432
Drug: 5 U-Turn
RxNorm normalized name: TURNIP
DrugBank: Turnip (DB10652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 U-Turn Test (5UTT) - smartphone-based assessment of U-turn speed, self-administered daily for 14 days
Trial: 36727801
Drug: Half-dose photodynamic
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose photodynamic therapy
Trial: 35999026
Drug: Marstacimab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marstacimab (300 mg, 150 mg, or 450 mg weekly doses based on inhibitor status)
Trial: 33753445
Drug: Prophylactic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic low molecular weight heparin (LMWH)
Trial: 34752255
Drug: Electric 3D
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric 3D toothbrush (Oral-B Pro-1000 with Oral-B Ortho head)
Trial: 34752255
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral-B Orthodontic brush)
Trial: 34913281
Drug: Antioxidant-rich dietary
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant-rich dietary intervention (3 meal boxes daily for 4 weeks)
Trial: 34602400
Drug: Celecoxib combined
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib combined with glucosamine hydrochloride therapy
Trial: 34602400
Drug: Celecoxib tablet
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib tablet therapy
Trial: 36307989
Drug: Topical gentamicin
RxNorm normalized name: gentamicin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gentamicin cream delivered via platform wound device (PWD)
Trial: 32246899
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of 4-fluoroamphetamine (4-FA)
Trial: 32246899
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of 4-fluoroamphetamine (4-FA) in 150 mL Royal Club bitter lemon drink
Trial: 32585392
Drug: Turmeric and
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric and mefenamic acid (500 mg and 250 mg respectively)
Trial: 32585392
Drug: Turmeric (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric (500 mg)
Trial: 32585392
Drug: Turmeric and
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric and mefenamic acid combination
Trial: 36251574
Drug: Neoadjuvant dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVACx6)
Trial: 35820575
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT; n = 24)
Trial: 33978382
Drug: miR‐182 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miR‐182 inhibitor
Trial: 33038141
Drug: 10 μg vaginal
RxNorm normalized name: Mycelex-G Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg vaginal estrogen therapy (ET) for 52 weeks
Trial: 32543021
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 μg) administered three times daily for 26 weeks
Trial: 32543021
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered three times daily for 26 weeks
Trial: 33402377
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy Skills Scale
Trial: 36000934
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment (8 rifamycin and 26 isoniazid monotherapy)
Trial: 33842907
Drug: Selenite 200
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenite 200 μg
Trial: 33842907
Drug: Selenite 50
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenite 50 μg
Trial: 35868015
Drug: High-carbohydrate diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate diet (CHO; 1 g CHO·kg ‐1 ·h ‐1)
Trial: 35868015
Drug: Low-carbohydrate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate placebo diet (PLA; <0.1 g CHO·kg ‐1 ·h ‐1)
Trial: 32799726
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and azithromycin
Trial: 32851421
Drug: CDP-choline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline (500 mg) with galantamine (16 mg)
Trial: 33577559
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of antiretroviral treatment (ART)
Trial: 38810093
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg)
Trial: 35190468
Drug: 10 mL 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 0.5% bupivacaine plus 133 mg liposomal bupivacaine (LB)
Trial: 35190468
Drug: 20 mL of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.5% bupivacaine
Trial: 33548194
Drug: CoronaVac 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 1.5 µg
Trial: 33548194
Drug: CoronaVac 3
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 3 µg
Trial: 33548194
Drug: CoronaVac 6
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 6 µg
Trial: 33548194
Drug: CoronaVac 3
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 3 µg (phase 1)
Trial: 33548194
Drug: CoronaVac 6
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac 6 µg (phase 1)
Trial: 32402509
Drug: Definitive high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definitive high-dose radiation therapy (RT)
Trial: 35294969
Drug: Daily multivitamin-multimineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin-multimineral (MVM) supplement
Trial: 36297081
Drug: CAF*TAU (co‐ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF*TAU (co‐ingestion of 3 g single dose of taurine and 6 mg/kg of caffeine)
Trial: 36297081
Drug: TAU (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (3 g single dose of taurine)
Trial: 33788483
Drug: Irrelevant acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrelevant acupoint prescription (Feiyang, Heding, Yingu, Tianfu, Xiabai)
Trial: 35438754
Drug: Degarelix (1-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (1-time subcutaneous dose of 240 mg)